Latigo Biotherapeutics, Inc. Common Stock (LTGO) - Total Liabilities
Based on the latest financial reports, Latigo Biotherapeutics, Inc. Common Stock (LTGO) has total liabilities worth $340.84 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See working capital position of Latigo Biotherapeutics, Inc. Common Stoc to evaluate short-term liquidity relative to the company's equity base.
Latigo Biotherapeutics, Inc. Common Stock - Total Liabilities Trend (2024–2025)
This chart illustrates how Latigo Biotherapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See how financially flexible is Latigo Biotherapeutics, Inc. Common Stoc to measure the company's free cash flow as a share of total liabilities.
Latigo Biotherapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Latigo Biotherapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
INVEX Controladora S.A.B. de C.V
MX:INVEXA
|
Mexico | MX$220.09 Billion |
|
KRN Heat Exchanger and Refrigeration
NSE:KRN
|
India | Rs-5.74 Billion |
|
Shaanxi Zhongtian Rocket Technology
SHE:003009
|
China | CN¥1.44 Billion |
|
Beijing Jingwei Hirain Technologies Co. Ltd. A
SHG:688326
|
China | CN¥6.00 Billion |
|
Shanghai Shibei Hi-Tech Co Ltd A
SHG:600604
|
China | CN¥12.49 Billion |
|
Lonkey Industrial Co Ltd Guangzhou
SHE:000523
|
China | CN¥1.23 Billion |
|
MetroCity Bankshares
NASDAQ:MCBS
|
USA | $3.95 Billion |
|
Amphastar P
NASDAQ:AMPH
|
USA | $975.61 Million |
Liability Composition Analysis (2024–2025)
This chart breaks down Latigo Biotherapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Latigo Biotherapeutics, Inc. Common Stoc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 5.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Latigo Biotherapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Latigo Biotherapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual total liabilities of Latigo Biotherapeutics, Inc. Common Stock from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $307.19 Million | +101.48% |
| 2024-12-31 | $152.46 Million | -- |
About Latigo Biotherapeutics, Inc. Common Stock
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting … Read more